Xenon Pharmaceuticals
XENE
163 hedge funds and large institutions have $2.19B invested in Xenon Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 25 closing their positions.
1,147% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $898K
16% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 25
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
3% more funds holding
Funds holding: 159 → 163 (+4)
0.42% more ownership
Funds ownership: 96.58% → 97% (+0.42%)
7% less capital invested
Capital invested by funds: $2.37B → $2.19B (-$177M)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$24.1M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$21.8M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$20.6M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$13.5M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$38.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.9M |
| 3 |
Millennium Management
New York
|
-$13.8M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$12.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ERSOT
176
Employees Retirement System of Texas
Austin,
Texas
| – | -$631K | -16,001 | Closed |
|
|
EGM
177
Engineers Gate Manager
New York
| – | -$567K | -14,383 | Closed |
|
|
E
178
Ergoteles
New York
| – | -$533K | -13,516 | Closed |
|
|
FRM
179
Fox Run Management
Greenwich,
Connecticut
| – | -$512K | -12,975 | Closed |
|
|
MSR
180
Main Street Research
Lakeville,
Connecticut
| – | -$394K | -10,000 | Closed |
|
|
JF
181
Jump Financial
Chicago,
Illinois
| – | -$305K | -7,725 | Closed |
|
182
Group One Trading
Chicago,
Illinois
| – | -$242K | -6,552 | Closed |
|
183
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$229K | -5,799 | Closed |
|
|
VF
184
Virtu Financial
New York
| – | -$221K | -5,604 | Closed |
|
185
ProShare Advisors
Bethesda,
Maryland
| – | -$204K | -5,172 | Closed |
|
|
HNWAG
186
High Net Worth Advisory Group
Naples,
Florida
| – | -$78.9K | -2,000 | Closed |
|
|
CG
187
Cutler Group
San Francisco,
California
| – | -$3K | -100 | Closed |
|
|
BTI
188
Blue Trust Inc
Alpharetta,
Georgia
| – | -$1K | -29 | Closed |
|
XENE Hedge Fund Activity: Q1 2023 in Review
163 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2023, worth a combined $2.19B — down 7.5% from $2.37B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new XENE positions and 25 closed out — a net gain of 4 holders — while 52 added to existing stakes and 46 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $24.1M. The largest seller was Redmile Group, cutting an estimated $38.2M.
- 163 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2023, up from 159 in Q4 2022.
- Funds reported $2.19B of Xenon Pharmaceuticals stock for Q1 2023, down 7.5% quarter-over-quarter.
- 29 funds opened new Xenon Pharmaceuticals positions in Q1 2023 and 25 closed out, a net change of +4 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2023 was Paradigm Biocapital Advisors, an estimated $24.1M added.
- The largest Xenon Pharmaceuticals seller in Q1 2023 was Redmile Group, an estimated $38.2M sold.
Based on aggregated 13F filings for Q1 2023.